Stay updated on Cabotegravir+VRC-HIVMAB075 in HIV-1 Viral Suppression Clinical Trial
Sign up to get notified when there's something new on the Cabotegravir+VRC-HIVMAB075 in HIV-1 Viral Suppression Clinical Trial page.

Latest updates to the Cabotegravir+VRC-HIVMAB075 in HIV-1 Viral Suppression Clinical Trial page
- Check3 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1 with no visible changes to study content, layout, or functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check25 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4 in the site footer. This is a minor housekeeping update with no impact on content or features.SummaryDifference0.0%

- Check47 days agoChange DetectedLocations section now lists state-specific sites (Alabama, California, Colorado, Illinois, Maryland, Missouri, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Washington) and the page revision is v3.3.3. The HHS Vulnerability Disclosure link was removed.SummaryDifference1%

- Check76 days agoChange DetectedPubMed publication listing text was updated and the footer revision number was changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedRemoved the general government funding operating status notice from the page; the study details and other content remain unchanged.SummaryDifference0.3%

- Check104 days agoChange DetectedResults First Posted on 2025-05-23 and updated study dates have been added to the page. This provides the study outcomes and current status for NCT03739996.SummaryDifference0.4%

Stay in the know with updates to Cabotegravir+VRC-HIVMAB075 in HIV-1 Viral Suppression Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabotegravir+VRC-HIVMAB075 in HIV-1 Viral Suppression Clinical Trial page.